{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:45Z","timestamp":1786980285673,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T00:00:00Z","timestamp":1331856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00520-012-1413-z","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T18:17:50Z","timestamp":1331835470000},"page":"2865-2872","source":"Crossref","is-referenced-by-count":56,"title":["Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial"],"prefix":"10.1007","volume":"20","author":[{"given":"Myra F.","family":"Barginear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Greben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Nier-Shoulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Budman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,16]]},"reference":[{"key":"1413_CR1","doi-asserted-by":"crossref","unstructured":"Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol 21 (Suppl 5):v274\u2013v276","DOI":"10.1093\/annonc\/mdq199"},{"key":"1413_CR2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146\u2013153","journal-title":"N Engl J Med"},{"key":"1413_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","volume":"12","author":"SR Deitcher","year":"2006","unstructured":"Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389\u2013396","journal-title":"Clin Appl Thromb Hemost"},{"key":"1413_CR4","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1046\/j.1538-7836.2003.00364.x","volume":"1","author":"A Iorio","year":"2003","unstructured":"Iorio A, Guercini F, Pini M (2003) Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 1:1906\u20131913","journal-title":"J Thromb Haemost"},{"key":"1413_CR5","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484\u20133488","journal-title":"Blood"},{"key":"1413_CR6","first-page":"I22","volume":"107","author":"C Kearon","year":"2003","unstructured":"Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I22\u2013I30","journal-title":"Circulation"},{"key":"1413_CR7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","volume":"160","author":"PO Hansson","year":"2000","unstructured":"Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160:769\u2013774","journal-title":"Arch Intern Med"},{"key":"1413_CR8","doi-asserted-by":"crossref","unstructured":"Perzborn E, Roehrig S, Straub A et al. (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Rev 10:61\u201375","DOI":"10.1038\/nrd3185"},{"key":"1413_CR9","doi-asserted-by":"crossref","unstructured":"Streiff MB (2010) The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 125 (Suppl 2):S128\u2013S133","DOI":"10.1016\/S0049-3848(10)70030-X"},{"key":"1413_CR10","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490\u20135505","journal-title":"J Clin Oncol"},{"key":"1413_CR11","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/archinte.160.13.2033","volume":"160","author":"RH White","year":"2000","unstructured":"White RH, Zhou H, Kim J, Romano PS (2000) A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 160:2033\u20132041","journal-title":"Arch Intern Med"},{"key":"1413_CR12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1076029608315165","volume":"15","author":"MF Barginear","year":"2009","unstructured":"Barginear MF, Lesser M, Akerman ML et al (2009) Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome. Clin Appl Thromb Hemost 15:263\u2013269","journal-title":"Clin Appl Thromb Hemost"},{"key":"1413_CR13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.164.14.1541","volume":"164","author":"PD Stein","year":"2004","unstructured":"Stein PD, Kayali F, Olson RE (2004) Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 164:1541\u20131545","journal-title":"Arch Intern Med"},{"key":"1413_CR14","unstructured":"Streiff MaKK (2011) Vena cava filters: A call to action. CHEST Physician Article"},{"key":"1413_CR15","doi-asserted-by":"crossref","unstructured":"PREPIC Study Group (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112:416\u2013422","DOI":"10.1161\/CIRCULATIONAHA.104.512834"},{"key":"1413_CR16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","volume":"338","author":"H Decousus","year":"1998","unstructured":"Decousus H, Leizorovicz A, Parent F et al (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d\u2019Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338:409\u2013415","journal-title":"N Engl J Med"},{"key":"1413_CR17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.43.6.1111","volume":"43","author":"JM Levin","year":"1993","unstructured":"Levin JM, Schiff D, Loeffler JS et al (1993) Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 43:1111\u20131114","journal-title":"Neurology"},{"key":"1413_CR18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF02016754","volume":"5","author":"KD Calligaro","year":"1991","unstructured":"Calligaro KD, Bergen WS, Haut MJ et al (1991) Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Ann Vasc Surg 5:186\u2013189","journal-title":"Ann Vasc Surg"},{"key":"1413_CR19","first-page":"12","volume":"109","author":"JR Cohen","year":"1991","unstructured":"Cohen JR, Tenenbaum N, Citron M (1991) Greenfield filter as primary therapy for deep venous thrombosis and\/or pulmonary embolism in patients with cancer. Surgery 109:12\u201315","journal-title":"Surgery"},{"key":"1413_CR20","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/archinte.1987.00370120113020","volume":"147","author":"JW Olin","year":"1987","unstructured":"Olin JW, Young JR, Graor RA et al (1987) Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med 147:2177\u20132179","journal-title":"Arch Intern Med"},{"key":"1413_CR21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19940115)73:2<493::AID-CNCR2820730240>3.0.CO;2-D","volume":"73","author":"D Schiff","year":"1994","unstructured":"Schiff D, DeAngelis LM (1994) Therapy of venous thromboembolism in patients with brain metastases. Cancer 73:493\u2013498","journal-title":"Cancer"},{"key":"1413_CR22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jama.279.6.458","volume":"279","author":"JD Douketis","year":"1998","unstructured":"Douketis JD, Kearon C, Bates S et al (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458\u2013462","journal-title":"JAMA"},{"key":"1413_CR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181","journal-title":"Semin Radiat Oncol"},{"key":"1413_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0038-1647487","volume":"65","author":"J Hirsh","year":"1991","unstructured":"Hirsh J (1991) Reliability of non-invasive tests for the diagnosis of venous thrombosis. Thromb Haemost 65:221\u2013222","journal-title":"Thromb Haemost"},{"key":"1413_CR25","volume-title":"Statistical methods for survival data analysis","year":"1992","unstructured":"Lee ET (ed) (1992) Statistical methods for survival data analysis, vol 2. Wiley, New York"},{"key":"1413_CR26","volume-title":"The errors of sampling of the survivorship table","year":"1926","unstructured":"Greenwood M (ed) (1926) The errors of sampling of the survivorship table. Her Majesty\u2019s Stationery Office, London, Vol. 33 of Reports on Public Health and Medical Patients"},{"key":"1413_CR27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/112972980800900204","volume":"9","author":"SP Stawicki","year":"2008","unstructured":"Stawicki SP, Sims CA, Sharma R et al (2008) Vena cava filters: a synopsis of complications and related topics. The J Vasc Access 9:102\u2013110","journal-title":"The J Vasc Access"},{"key":"1413_CR28","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729\u20131735","journal-title":"Arch Intern Med"},{"key":"1413_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11936-002-0003-7","volume":"4","author":"SR Deitcher","year":"2002","unstructured":"Deitcher SR, Carman TL (2002) Deep venous thrombosis and pulmonary embolism. Curr Treat Options Cardiovasc Med 4:223\u2013238","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"1413_CR30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","volume":"349","author":"HR Buller","year":"2003","unstructured":"Buller HR, Davidson BL, Decousus H et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695\u20131702","journal-title":"N Engl J Med"},{"key":"1413_CR31","unstructured":"Akl EA, Vasireddi SR, Gunukula S et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev:CD006649"},{"key":"1413_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","volume":"100","author":"S Siragusa","year":"1996","unstructured":"Siragusa S, Cosmi B, Piovella F et al (1996) Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100:269\u2013277","journal-title":"Am J Med"},{"key":"1413_CR33","doi-asserted-by":"crossref","first-page":"844S","DOI":"10.1378\/chest.08-0761","volume":"133","author":"SM Bates","year":"2008","unstructured":"Bates SM, Greer IA, Pabinger I et al (2008) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:844S\u2013886S","journal-title":"Chest"},{"key":"1413_CR34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/01.RVI.0000203418-39769.0D","volume":"17","author":"JA Kaufman","year":"2006","unstructured":"Kaufman JA, Kinney TB, Streiff MB et al (2006) Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 17:449\u2013459","journal-title":"J Vasc Interv Radiol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1413-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1413-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1413-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T05:44:43Z","timestamp":1561441483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1413-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,16]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1413-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,16]]}}}